GSK_ Annual_Report_2021-22

167 Notes to the Standalone Financial Statements for the year ended March 31, 2022 Note 55 : Disclosure pursuant to Ind AS 105 “Non-current assets held for sale and discontinued operations”: (i) Transfer of Iodex and Ostocalcium Brands : The Board of Directors (‘Board’) of the Company at their meeting held on July 26, 2021 had approved the transfer of the trademarks pertaining to ‘Iodex’ and ‘Ostocalcium’ brands (“ Brands”) in India along with legal, economic, commercial and marketing rights of such brands and other identified assets to GlaxoSmithKline Asia Private Limited with respective values aggregating ` 1649,01.00 lakhs. The transaction was consummated and the consideration was received by the company during the year after the receipt of shareholders’ and regulatory approvals. Consequently, the transfer has been disclosed as Discontinued Operations in accordance with Ind AS 105 “Non-Current Assets Held for Sale and Discontinued Operations”. The previous periods have been restated to give effect to the presentation requirements of Ind AS 105. (ii) Financial performance related to discontinued operations: ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 Revenue from operations 298,04.68 273,26.05 Total income 298,04.68 273,26.05 Expenses Cost of materials consumed (1,05.73) 24.01 Purchases of stock-in-trade 54,75.02 57,02.26 Changes in inventories of finished goods, stock-in-trade and work-in-progress 3,28.23 (1,40.54) Depreciation and amortisation expense 39.59 67.87 Other expenses 168,15.25 120,21.67 Total expenses 225,52.36 176,75.27 Profit before tax 72,52.32 96,50.78 Tax Expense : Current tax 19,98.87 25,62.94 Profit from discontinued operations after tax 52,53.45 70,87.84 Gain on Sale of brands and other identified assets before tax 1635,65.34 - Tax on above 374,23.75 - Gain on Sale of brands and other identified assets (net of tax) 1261,41.59 - (iii) Cash flow disclosure with respect to discontinued operations: ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 Cash flow from operating activities 68,71.24 99,10.81 Cash flow from investing activities 1561,38.28 -